Avidity has reported that in vitro treatment of DM1 myotubes partially corrected alternative splicing errors, while a single dose of 2 mg/kg administrated in non-human primates reduced DMPK mRNAs by ~75% over 12 weeks in skeletal muscles [125]. This evidence concerns the gene DMPK and myotonic dystrophy type 1.